Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 99c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q1 EPS of ($0.09), $0.99 better than the analyst estimate of ($1.08). Revenue for the quarter came in at $140 thousand versus the consensus estimate of $33.31 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Blackstone to invest $30B in AI data centers in Japan over the next 3 to 5 years, says president and COO Jonathan Gray - Nikkei
• Texas Capital Securities Reiterates Buy Rating on Texas Pacific Land Trust (TPL)